for Journals by Title or ISSN
for Articles by Keywords
help
Journal Cover The Medical Letter
  [SJR: 0.314]   [H-I: 16]   [8 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 0025-732X - ISSN (Online) 1523-2859
   Published by The Medical Letter, Inc Homepage  [1 journal]
  • Comparison Table: Drugs for Postmenopausal Osteoporosis (online only)
    • Authors: admin
      Abstract: Date:  June 19, 2017 Issue #:  1523 Summary:  View the Comparison Table: Drugs for Postmenopausal Osteoporosis
      PubDate: Mon, 12 Jun 2017 19:34:04 +000
       
  • Riboflavin (Photrexa) and Ultraviolet Light for Progressive Keratoconus
    • Authors: admin
      Abstract: Date:  June 19, 2017 Issue #:  1523 Summary:  The FDA has approved the ophthalmic solutionsriboflavin 5'-phosphate in 20% dextran (PhotrexaViscous – Avedro) and riboflavin 5'-phosphate alone(Photrexa) for use with ultraviolet A (UVA) light(KXL System) in the corneal collagen cross-linkingtreatment of two corneal disorders: progressivekeratoconus and corneal ectasia following refractivesurgery. It is the first corneal collagen cross-linking(CXL) treatment to be approved by the FDA.
      PubDate: Mon, 12 Jun 2017 19:13:26 +000
       
  • Obalon Balloon System - Another Gastric Balloon for Weight Loss
    • Authors: admin
      Abstract: Date:  June 19, 2017 Issue #:  1523 Summary:  The FDA has approved the Obalon Balloon System(Obalon), a swallowable intragastric gas-filled balloondevice, to facilitate weight loss in adults with a bodymass index (BMI) of 30-40 kg/m2 who have not beenable to lose weight through diet and exercise. Twoother gastric balloon devices, ReShape and Orbera,were approved earlier.
      PubDate: Wed, 31 May 2017 12:17:11 +000
       
  • Abaloparatide (Tymlos) for Postmenopausal Osteoporosis
    • Authors: admin
      Abstract: Date:  June 19, 2017 Issue #:  1523 Summary:  The FDA has approved abaloparatide (Tymlos –Radius Health), a synthetic analog of humanparathyroid hormone related peptide, for treatmentof postmenopausal women with osteoporosis whoare at high risk for fracture. Abaloparatide is thesecond parathyroid hormone receptor agonist to beapproved for this indication; teriparatide (Forteo –Lilly), a recombinant parathyroid hormone analog,was the first. They are the only drugs approvedfor treatment of osteoporosis that stimulate boneformation. Other drugs used for this indication inhibitbone resorption.
      PubDate: Wed, 17 May 2017 11:01:14 +000
       
  • Acetylcysteine (Cetylev) for Acetaminophen Overdose
    • Authors: admin
      Abstract: Date:  June 19, 2017 Issue #:  1523 Summary:  The FDA has approved an effervescent tabletformulation of acetylcysteine (Cetylev – Arbor) toprevent or lessen hepatic injury after acetaminophenoverdose. Acetylcysteine has been available for yearsin an IV solution (Acetadote, and generics) and an oralsolution for the same indication; use of the oral solutionhas been limited by its unpleasant odor and taste.
      PubDate: Wed, 17 May 2017 11:00:46 +000
       
  • Ocrelizumab (Ocrevus) for MS
    • Authors: admin
      Abstract: Date:  June 19, 2017 Issue #:  1523 Summary:  The FDA has approved ocrelizumab (Ocrevus –Genentech), a humanized anti-CD20 monoclonalantibody, for treatment of adults with primaryprogressive or relapsing multiple sclerosis (MS). It is thefirst anti-CD20 monoclonal antibody to be approved fortreatment of MS and the first disease-modifying drugto be approved in the US for primary progressive MS.
      PubDate: Wed, 19 Apr 2017 12:13:29 +000
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.198.148.176
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016